Developmental programming: insulin sensitizer treatment improves reproductive function in prenatal testosterone-treated female sheep.
Prenatal testosterone (T) excess causes reproductive and metabolic disruptions including insulin resistance, attributes of women with polycystic ovary syndrome. This study tested the hypothesis that insulin resistance contributes toward severity of reproductive disruptions in prenatally T-treated females. Pregnant sheep were injected im with 100 mg of T-propionate semiweekly from d 30-90 of gestation. Immediately after the first breeding season, a subset of controls and prenatal T-treated (TR) sheep were administered an insulin sensitizer (rosiglitazone; 8 mg/d) orally for 8 months. Untreated control and prenatal T-treated females (T group) were studied in parallel. Biochemical analyses revealed rosiglitazone to be safe for use in sheep. Glucose tolerance tests performed before and after the insulin sensitizer treatment found that insulin sensitizer decreased cumulative insulin, cumulative insulin/glucose ratio, and insulin area under the curve by about 50% and increased the insulin sensitivity index by about 70% in the TR compared with the T group. Twenty percent of TR females showed a reduced number of cycles in the second relative to first breeding season as opposed to 80% of T group females showing such deterioration. Insulin sensitizer treatment also decreased the number of aberrant cycles (>/=18 d) during the second breeding season in the TR group relative to the first as opposed to the T group females showing an increase in the second breeding season relative to the first. These findings provide evidence that insulin sensitizer treatment prevents further deterioration of the reproductive axis in prenatal T-treated sheep, a finding of translational relevance to women with polycystic ovary syndrome.
Veiga-Lopez
Almudena
A
Department of Pediatrics and Reproductive Sciences Program, University of Michigan, Ann Arbor, Michigan 48109-0404, USA.
Lee
James S
JS
Padmanabhan
Vasantha
V
D000818:Animals; D004353:Drug Evaluation, Preclinical; D030762:Estrous Cycle / Q000097:blood / Q000187:drug effects / Q000378:metabolism; D005260:Female; D047109:Fetal Development / Q000187:drug effects*; D007004:Hypoglycemic Agents / Q000494:pharmacology; D007328:Insulin / Q000378:metabolism* / Q000494:pharmacology; D007333:Insulin Resistance / Q000502:physiology; D008099:Liver / Q000378:metabolism / Q000503:physiopathology; D011085:Polycystic Ovary Syndrome / Q000139:chemically induced / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D011247:Pregnancy; D011297:Prenatal Exposure Delayed Effects / Q000139:chemically induced* / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D012098:Reproduction / Q000187:drug effects* / Q000502:physiology; D000077154:Rosiglitazone; D012756:Sheep; D013739:Testosterone / Q000009:adverse effects* / Q000494:pharmacology; D045162:Thiazolidinediones / Q000494:pharmacology / Q000627:therapeutic use*
D007004:Hypoglycemic Agents; D007328:Insulin; D045162:Thiazolidinediones; D000077154:Rosiglitazone; D013739:Testosterone